Tumor Lysis Syndrome — Prevention & Treatment

Key Points

• Risk stratification before cancer therapy is the most effective TLS intervention.
• Hyperkalemia is the most immediately dangerous electrolyte abnormality and requires emergency treatment.
• Allopurinol prevents new uric acid formation but does not rapidly remove existing uric acid.
• Rasburicase rapidly lowers uric acid and is used for high-risk or established TLS when not contraindicated.
• Do not give routine calcium for asymptomatic hypocalcemia in marked hyperphosphatemia.
• G6PD deficiency is a major contraindication to rasburicase because of hemolysis and methemoglobinemia risk.
• Frequent serial labs are essential because TLS can evolve over hours.
• Dialysis should be initiated promptly for refractory electrolyte or volume complications rather than delayed until creatinine becomes extreme.

Algorithm

1. Before cancer therapy, determine malignancy-specific TLS risk, tumor burden, renal function, uric acid, and electrolyte baseline.
2. Start appropriate IV hydration and urate-lowering prophylaxis according to risk.
3. Monitor potassium, phosphate, calcium, uric acid, creatinine, LDH, urine output, and ECG at a frequency matched to risk.
4. Treat hyperkalemia immediately and manage phosphate accumulation while avoiding unnecessary calcium.
5. Use rasburicase for high-risk or established significant hyperuricemia after checking contraindications.
6. Escalate monitoring and involve nephrology when AKI, oliguria, or electrolyte abnormalities progress.
7. Initiate kidney replacement therapy for refractory hyperkalemia, severe phosphate load, volume overload, or other accepted indications.
8. Continue surveillance through the period of expected tumor lysis after therapy.

Clinical Synopsis & Reasoning

TLS most often occurs in highly proliferative, treatment-sensitive hematologic malignancies such as Burkitt lymphoma, acute leukemias, and bulky high-grade lymphomas, but it can occur with solid tumors and occasionally spontaneously before therapy. Risk is determined by tumor burden, proliferation rate, baseline uric acid, renal function, expected treatment response, dehydration, and nephrotoxic exposures. New targeted therapies can produce rapid cytoreduction and should be considered when estimating risk even when traditional chemotherapy is not being used.

Laboratory TLS is characterized by characteristic changes in uric acid, potassium, phosphate, and calcium around cancer treatment, while clinical TLS adds organ effects such as AKI, arrhythmia, seizure, or death. Hyperkalemia is the most immediately lethal electrolyte abnormality. Hyperphosphatemia complexes with calcium, contributing to hypocalcemia and calcium-phosphate deposition in the kidneys and tissues. Uric acid can precipitate within renal tubules, but modern rasburicase use has shifted some renal injury toward phosphate-driven mechanisms.

Differentiate TLS from sepsis-associated AKI, medication nephrotoxicity, rhabdomyolysis, adrenal insufficiency, and other causes of hyperkalemia or hyperphosphatemia. Obtain serial potassium, phosphate, calcium, uric acid, creatinine, LDH, and ECG in patients at meaningful risk. The laboratory trend is more important than any isolated value. Symptoms can include nausea, vomiting, weakness, muscle cramps, tetany, altered mental status, seizure, oliguria, or dysrhythmia.

Treatment Strategy & Disposition

Prevention begins before cytotoxic therapy when possible. Provide isotonic IV hydration sufficient to maintain renal perfusion and urine output while avoiding fluid overload in patients with heart or kidney disease. Allopurinol prevents formation of new uric acid but does not rapidly lower uric acid that is already elevated. It is appropriate for many intermediate-risk patients when started before treatment. Rasburicase enzymatically converts uric acid to soluble allantoin and is preferred for high-risk TLS or established significant hyperuricemia when not contraindicated.

Treat hyperkalemia immediately according to standard emergency principles, including IV calcium for cardiac membrane instability, intracellular shifting, and definitive potassium removal. Restrict unnecessary potassium and phosphate intake. Treat symptomatic hypocalcemia with calcium, but avoid routine calcium administration for asymptomatic hypocalcemia when severe hyperphosphatemia is present because calcium-phosphate precipitation can worsen tissue and kidney injury. Phosphate binders can be used as adjuncts, but severe phosphate load may require dialysis.

Consult nephrology early for worsening AKI, oliguria, refractory hyperkalemia, severe hyperphosphatemia, symptomatic hypocalcemia driven by phosphate, volume overload, or other dialysis indications. Continuous modalities may be useful when ongoing tumor lysis continually releases solute. Rasburicase is contraindicated in G6PD deficiency because it can cause severe hemolysis and methemoglobinemia. Blood samples for uric acid after rasburicase require chilled handling because the drug can continue degrading uric acid ex vivo and produce falsely low results.

Epidemiology / Risk Factors

• TLS is most common in rapidly proliferating, treatment-sensitive hematologic malignancies with high tumor burden.
• Modern targeted agents can trigger TLS in diseases not historically considered high risk.
• Baseline kidney dysfunction and dehydration increase clinical severity.
• Prophylaxis has reduced severe uric-acid nephropathy in many high-risk treatment protocols.
• Spontaneous TLS is less common but clinically important.

Investigations

Urate-Lowering Strategies

Pharmacology

Prognosis / Complications

• Early recognition and prophylaxis markedly improve outcomes.
• Severe hyperkalemia, arrhythmia, seizure, and multiorgan failure can cause sudden death.
• AKI increases chemotherapy complexity and can delay or alter cancer treatment.
• Patients requiring dialysis can still recover kidney function when TLS is controlled and the underlying malignancy responds.
• Prognosis also depends heavily on the underlying cancer and its response to therapy.

Patient Education / Counseling

• Explain why frequent blood tests are necessary during the high-risk period even when the patient feels well.
• Maintain hydration as directed and avoid potassium or phosphate supplements unless specifically prescribed.
• Report muscle weakness, palpitations, numbness, cramps, reduced urine, confusion, or seizure symptoms immediately.
• Patients prescribed allopurinol should understand that it is preventive and should be taken according to the oncology plan.
• Tell the care team about known G6PD deficiency or prior reactions before rasburicase is given.
• Continue oncology and renal follow-up after an episode because kidney function and future treatment plans may need adjustment.

Notes

TLS prevention must be planned with the anticipated cancer response in mind. A patient receiving a highly effective targeted therapy can become high risk even if the older chemotherapy-era risk category seemed lower.

The modern emergency focus is not only uric acid. Potassium and phosphate can rise quickly enough to become the dominant life threats, so serial chemistry and ECG monitoring are central to care.

References

1. National Cancer Institute Tumor Lysis References — Link
2. American Society of Clinical Oncology Resources — Link